Public

Erectile Dysfunction Is Already a Cardiovascular Risk Marker. New Data Link It to Glaucoma Too

Retatrutide Isn’t Approved. Online, ‘Reta’ Is Already a Weight-Loss Brand

Pembrolizumab Just Lost a Head-to-Head Survival Fight

SMA Treatment Finally Reaches the Muscle

Cardiology Has Long Said “Eat Whole Grains.” New Evidence Asks How Much

Novo’s $1.4B Orbis Deal Bets on a New Route to Oral Cardiometabolic Drugs

HER2-Mutant Lung Cancer Just Moved Into First Line

One Psychedelic Dose Is Now a Phase III Argument

Can Belgium Turn Routine GP Data Into Cardiovascular Prevention?
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
